HC Wainwright reissued their buy rating on shares of TG Therapeutics (NASDAQ:TGTX) in a research note released on Tuesday morning. The brokerage currently has a $33.00 price objective on the biopharmaceutical company’s stock.
A number of other analysts have also recently commented on TGTX. Zacks Investment Research cut shares of TG Therapeutics from a hold rating to a sell rating in a research report on Saturday, January 13th. BidaskClub raised shares of TG Therapeutics from a sell rating to a hold rating in a research report on Thursday, January 11th. B. Riley reissued a buy rating and set a $21.50 price objective on shares of TG Therapeutics in a research report on Monday, December 11th. SunTrust Banks reissued a buy rating and set a $28.00 price objective on shares of TG Therapeutics in a research report on Tuesday, October 3rd. Finally, ValuEngine cut shares of TG Therapeutics from a hold rating to a sell rating in a research report on Monday, October 16th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $25.50.
Shares of TG Therapeutics (NASDAQ TGTX) traded down $0.02 on Tuesday, reaching $9.35. 726,212 shares of the company’s stock were exchanged, compared to its average volume of 1,320,000. The company has a market capitalization of $658.84, a PE ratio of -4.84 and a beta of 1.30. TG Therapeutics has a twelve month low of $4.10 and a twelve month high of $15.35.
TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.05). The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 73,217.77% and a negative return on equity of 151.21%. research analysts forecast that TG Therapeutics will post -1.87 earnings per share for the current fiscal year.
In other news, CFO Sean A. Power sold 32,006 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $8.50, for a total transaction of $272,051.00. Following the transaction, the chief financial officer now owns 517,464 shares of the company’s stock, valued at approximately $4,398,444. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 16.70% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp raised its holdings in shares of TG Therapeutics by 274.4% in the 2nd quarter. State Street Corp now owns 2,638,683 shares of the biopharmaceutical company’s stock worth $26,515,000 after acquiring an additional 1,933,896 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of TG Therapeutics by 20.6% in the 2nd quarter. Franklin Resources Inc. now owns 2,339,166 shares of the biopharmaceutical company’s stock worth $23,509,000 after acquiring an additional 398,916 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of TG Therapeutics by 14.3% in the 2nd quarter. Vanguard Group Inc. now owns 2,046,427 shares of the biopharmaceutical company’s stock worth $20,566,000 after acquiring an additional 255,844 shares during the last quarter. Columbus Circle Investors raised its holdings in shares of TG Therapeutics by 9.8% in the 3rd quarter. Columbus Circle Investors now owns 1,532,911 shares of the biopharmaceutical company’s stock worth $18,165,000 after acquiring an additional 136,515 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in shares of TG Therapeutics by 29.0% in the 2nd quarter. Northern Trust Corp now owns 598,626 shares of the biopharmaceutical company’s stock worth $6,016,000 after acquiring an additional 134,463 shares during the last quarter. Institutional investors own 50.41% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was first reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.truebluetribune.com/2018/01/20/tg-therapeutics-tgtx-given-buy-rating-at-hc-wainwright.html.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.